CDA Technology is a
Game Changer.
ANPAC BIO'S CDA (CANCER DIFFERENTIATION ANALYSIS) IS A REVOLUTIONARY TECHNOLOGY.
LEARN MORE
Results Speak.
20+

CANCER TYPES

~150

SCREENED OUT CASES

75%
TO
90%

ACCURACY RATE

100K+

CONFIRMED TESTS

About Anpac Bio

Decades of research by the world’s most respected cancer scientists and physicians consistently reveals one conclusion:

Most people can survive cancer if the disease is caught early.

This fact led Anpac Bio Co-Founders, Dr. Chris Yu and Dr. Herbert Yu, to ask the question that ultimately launched the company:

“What if we could detect cancer before tumors start?”

Achieving that goal became the Anpac Co-Founders’ quest. They began breaking the problem apart—drawing on expertise in:

  • Cancer research
  • Bio-chemistry
  • Chemistry
  • Nano-technology
  • Surface science
  • Material science
  • Detection
  • Physics
  • Engineering and manufacturing

Together they founded Anpac Bio-Medical Science Co., Ltd. in 2008, bringing together a multi-national team of medical, biomedical and nanotechnology scientists, and engineering experts. Their unique, cross-disciplinary approach combines numerous fields of science, medicine and engineering to achieve vastly superior early cancer screening and detection technology.

LEARN MORE

Meet the People Who Are Changing the Game